What Happened? Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Incidence of third generation cephalosporin-resistant bacteria (3GCRB)
研究概览
简要总结
Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic.
详细描述
The COVID-19 pandemic accelerated/exacerbated resistance rates for key pathogens. Specifically, incidence of extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBLPE), carbapenem-resistant bacteria (CRB), methicillin-resistant Staphyloccoccus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and C. difficile infections (CDI) will be higher in the pandemic time period (Pandemic, March 2020 - February 2025) compared to the pre-pandemic period (Pre-Pandemic, March 2018 - February 2020).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •• Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between March 2018 and August
- •>18 years old
排除标准
- •• Outpatient visit
- •Not admitted to an inpatient or observation status
结局指标
主要结局
Incidence of third generation cephalosporin-resistant bacteria (3GCRB)
时间窗: 5 Months
Incidence of third generation cephalosporin-resistant bacteria (3GCRB)
次要结局
- Incidence of CRB(5 Months)
- Incidence of other pathogens(August 2021)
- Incidence of ESBLPE(5 months)
- Incidence of nosocomial infections(5 Months)
- Incidence of clinical outcomes(5 Months)